- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07221474
Un estudio de V940/Placebo + Pembrolizumab y quimioterapia en el cáncer de pulmón de células no pequeñas metastásico escamoso (V940-013) (INTerpath-13)
Un estudio de fase 2, aleatorizado, doble ciego y controlado con placebo de V940 en combinación con pembrolizumab y quimioterapia como tratamiento de primera línea para participantes con CNMP escamoso metastásico (INTerpath-013)
Researchers want to know if intismeran autogene (the study treatment) given with pembrolizumab and chemotherapy can treat metastatic treatment-naive squamous non-small cell lung cancer (NSCLC). Intismeran autogene is designed to help a person's immune system attack their specific cancer.
The goal of this study is to learn if people who receive intismeran autogene with pembrolizumab and chemotherapy live longer overall and without the cancer growing or spreading compared to people who receive placebo with pembrolizumab and chemotherapy. A placebo looks like the study treatment but has no study treatment in it. Using a placebo helps researchers better understand the effects of the study treatment.
Descripción general del estudio
Estado
Intervención / Tratamiento
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 2
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Toll Free Number
- Número de teléfono: 1-888-577-8839
- Correo electrónico: Trialsites@msd.com
Ubicaciones de estudio
-
-
Buenos Aires
-
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina, C1426ANZ
- Reclutamiento
- Instituto Alexander Fleming ( Site 0201)
-
Contacto:
- Study Coordinator
- Número de teléfono: +541132218956
-
Ciudad Autonoma de Buenos Aires., Buenos Aires, Argentina, C1199ABB
- Reclutamiento
- Hospital Italiano de Buenos Aires ( Site 0200)
-
Contacto:
- Study Coordinator
- Número de teléfono: +541149590497
-
Mar del Plata, Buenos Aires, Argentina, B7600FZO
- Reclutamiento
- Instituto de Investigaciones Clínicas Mar del Plata ( Site 0205)
-
Contacto:
- Study Coordinator
- Número de teléfono: +5492235937663
-
-
Buenos Aires F.D.
-
Caba., Buenos Aires F.D., Argentina, C1430EGF
- Reclutamiento
- Clinica Adventista Belgrano ( Site 0206)
-
Contacto:
- Study Coordinator
- Número de teléfono: +5491140141500
-
-
Santa Fe Province
-
Rosario, Santa Fe Province, Argentina, S2000DSV
- Reclutamiento
- Fundacion Estudios Clinicos ( Site 0207)
-
Contacto:
- Study Coordinator
- Número de teléfono: +5493413168137
-
Rosario, Santa Fe Province, Argentina, S2000DSV
- Reclutamiento
- Sanatorio Parque ( Site 0203)
-
Contacto:
- Study Coordinator
- Número de teléfono: +543874044942
-
-
-
-
New South Wales
-
Westmead, New South Wales, Australia, 2145
- Reclutamiento
- Westmead Hospital ( Site 0400)
-
Contacto:
- Study Coordinator
- Número de teléfono: +61298455555
-
-
Queensland
-
Woolloongabba, Queensland, Australia, 4102
- Reclutamiento
- Princess Alexandra Hospital ( Site 0403)
-
Contacto:
- Study Coordinator
- Número de teléfono: +61731762111
-
-
Western Australia
-
Nedlands, Western Australia, Australia, 6009
- Reclutamiento
- One Clinical Research ( Site 0402)
-
Contacto:
- Study Coordinator
- Número de teléfono: +6186279 9466
-
-
-
-
-
Antofagasta, Chile, 1263521
- Reclutamiento
- Bradford Hill Norte ( Site 0308)
-
Contacto:
- Study Coordinator
- Número de teléfono: 56442023631
-
-
Region M. de Santiago
-
Santiago, Region M. de Santiago, Chile, 7500653
- Reclutamiento
- Centro de Estudios Clínicos SAGA ( Site 0307)
-
Contacto:
- Study Coordinator
- Número de teléfono: +56991612199
-
Santiago, Region M. de Santiago, Chile, 8420383
- Reclutamiento
- Bradfordhill ( Site 0301)
-
Contacto:
- Study Coordinator
- Número de teléfono: +56 2 29490970
-
Santiago, Region M. de Santiago, Chile, 7500921
- Reclutamiento
- Fundación Arturo López Pérez ( Site 0300)
-
Contacto:
- Study Coordinator
- Número de teléfono: 56224205098
-
-
-
-
-
Seoul, Corea del Sur, 05505
- Reclutamiento
- Asan Medical Center ( Site 0503)
-
Contacto:
- Study Coordinator
- Número de teléfono: +82230103215
-
Seoul, Corea del Sur, 06351
- Reclutamiento
- Samsung Medical Center ( Site 0502)
-
Contacto:
- Study Coordinator
- Número de teléfono: +82234101132
-
-
Kyonggi-do
-
Goyang-si, Kyonggi-do, Corea del Sur, 10408
- Reclutamiento
- National Cancer Center ( Site 0504)
-
Contacto:
- Study Coordinator
- Número de teléfono: +82319200114
-
Seongnam-si, Kyonggi-do, Corea del Sur, 13620
- Reclutamiento
- Seoul National University Bundang Hospital ( Site 0500)
-
Contacto:
- Study Coordinator
- Número de teléfono: +82317877071
-
-
North Chungcheong
-
Cheongju-si, North Chungcheong, Corea del Sur, 28644
- Reclutamiento
- Chungbuk National University Hospital-Internal medicine ( Site 0501)
-
Contacto:
- Study Coordinator
- Número de teléfono: 043-269-6015
-
-
-
-
-
Barcelona, España, 08035
- Reclutamiento
- Hospital Universitari Vall d''Hebron ( Site 1310)
-
Contacto:
- Study Coordinator
- Número de teléfono: +34 93 254 3450
-
Madrid, España, 28034
- Reclutamiento
- Hospital Ramon y Cajal ( Site 1314)
-
Contacto:
- Study Coordinator
- Número de teléfono: +34 91 336 82 63
-
Madrid, España, 28040
- Reclutamiento
- Hospital Clinico San Carlos... ( Site 1313)
-
Contacto:
- Study Coordinator
- Número de teléfono: +34 913303000
-
Seville, España, 41009
- Reclutamiento
- Hospital Universitario Virgen Macarena-Unidad de Investigación Oncológica ( Site 1312)
-
Contacto:
- Study Coordinator
- Número de teléfono: +34 671560092
-
-
Barcelona
-
Hospitalet, Barcelona, España, 08907
- Reclutamiento
- ICO L Hospitalet ( Site 1311)
-
Contacto:
- Study Coordinator
- Número de teléfono: +34 93 260 77 44
-
-
Cadiz
-
Jerez de la Frontera, Cadiz, España, 11407
- Reclutamiento
- Hospital Jerez de la Frontera-UGC Oncología ( Site 1315)
-
Contacto:
- Study Coordinator
- Número de teléfono: 956 03 22 44
-
-
-
-
Florida
-
Tampa, Florida, Estados Unidos, 33612
- Reclutamiento
- Moffitt Cancer Center ( Site 0021)
-
Contacto:
- Study Coordinator
- Número de teléfono: 813-745-7363
-
-
Michigan
-
Ann Arbor, Michigan, Estados Unidos, 48105
- Reclutamiento
- VA Ann Arbor Healthcare System ( Site 0019)
-
Contacto:
- Study Coordinator
- Número de teléfono: 734-769-7100
-
-
Missouri
-
St Louis, Missouri, Estados Unidos, 63110
- Reclutamiento
- Washington University School of Medicine ( Site 0024)
-
Contacto:
- Study Coordinator
- Número de teléfono: 314-362-5000
-
-
New Jersey
-
Paramus, New Jersey, Estados Unidos, 07652
- Reclutamiento
- Valley Health Systems - Ridgewood Campus ( Site 0010)
-
Contacto:
- Study Coordinator
- Número de teléfono: 201-634-5578
-
-
New York
-
Albany, New York, Estados Unidos, 12206
- Reclutamiento
- New York Oncology Hematology (NYOH) - Albany Medical Center ( Site 9001)
-
Contacto:
- Study Coordinator
- Número de teléfono: 518-489-0044
-
-
Ohio
-
Cleveland, Ohio, Estados Unidos, 44195
- Reclutamiento
- Cleveland Clinic - Ohio ( Site 0016)
-
Contacto:
- Study Coordinator
- Número de teléfono: 216-445-7855
-
-
Oregon
-
Corvallis, Oregon, Estados Unidos, 97330
- Reclutamiento
- Good Samaritan Regional Medical Center-Samaritan Pastega Regional Cancer Center ( Site 0025)
-
Contacto:
- Study Coordinator
- Número de teléfono: 541-768-4950
-
-
Tennessee
-
Nashville, Tennessee, Estados Unidos, 37203
- Reclutamiento
- Tennessee Oncology, PLLC - Elliston Place Plaza Medical Oncology & Hematology ( Site 9000)
-
Contacto:
- Study Coordinator
- Número de teléfono: 615-961-9469
-
-
Texas
-
Austin, Texas, Estados Unidos, 78745
- Reclutamiento
- Texas Oncology - Central/South Texas ( Site 8002)
-
Contacto:
- Study Coordinator
- Número de teléfono: 512-427-9400
-
-
Virginia
-
Fairfax, Virginia, Estados Unidos, 22031
- Reclutamiento
- Virginia Cancer Specialists ( Site 0003)
-
Contacto:
- Study Coordinator
- Número de teléfono: 730-280-5390
-
-
Washington
-
Seattle, Washington, Estados Unidos, 98104
- Reclutamiento
- Swedish Medical Center-Swedish Cancer Institute ( Site 0023)
-
Contacto:
- Study Coordinator
- Número de teléfono: 855-922-6237
-
-
-
-
Cote-d Or
-
Dijon, Cote-d Or, Francia, 21000
- Reclutamiento
- Centre Georges François Leclerc ( Site 0805)
-
Contacto:
- Study Coordinator
- Número de teléfono: +33345348051
-
-
Pays de la Loire Region
-
Angers, Pays de la Loire Region, Francia, 49055
- Reclutamiento
- Institut de Cancérologie de l'Ouest ( Site 0801)
-
Contacto:
- Study Coordinator
- Número de teléfono: +33 (0)2.44 85 35 54
-
-
Puy-de-Dome
-
Clermont-Ferrand, Puy-de-Dome, Francia, 63001
- Reclutamiento
- CHU GABRIEL MONTPIED ( Site 0802)
-
Contacto:
- Study Coordinator
- Número de teléfono: +33473754440
-
-
-
-
-
Milan, Italia, 20132
- Reclutamiento
- Ospedale San Raffaele-Oncologia Medica ( Site 1002)
-
Contacto:
- Study Coordinator
- Número de teléfono: +390226436633
-
Milan, Italia, 20133
- Reclutamiento
- Fondazione IRCCS Istituto Nazionale Dei Tumori ( Site 1000)
-
Contacto:
- Study Coordinator
- Número de teléfono: +390223903829
-
Perugia, Italia, 06132
- Reclutamiento
- AO Santa Maria della Misericordia-Oncology Department ( Site 1005)
-
Contacto:
- Study Coordinator
- Número de teléfono: +390755782661
-
Roma, Italia, 00168
- Reclutamiento
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore ( Site 1001)
-
Contacto:
- Study Coordinator
- Número de teléfono: 00390630154277
-
-
Emilia-Romagna
-
Ravenna, Emilia-Romagna, Italia, 48121
- Reclutamiento
- Ospedale Santa Maria delle Croci-Dipartimento Oncoematologico ( Site 1004)
-
Contacto:
- Study Coordinator
- Número de teléfono: +390544285247
-
-
-
-
Greater Poland Voivodeship
-
Poznan, Greater Poland Voivodeship, Polonia, 60-569
- Reclutamiento
- Wielkopolskie Centrum Pulmonologii i Torakochirurgii ( Site 1101)
-
Contacto:
- Study Coordinator
- Número de teléfono: +48616654242
-
-
Masovian Voivodeship
-
Warsaw, Masovian Voivodeship, Polonia, 02-781
- Reclutamiento
- Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie ( Site 1100)
-
Contacto:
- Study Coordinator
- Número de teléfono: +48225463066
-
-
Podkarpackie Voivodeship
-
Przemyśl, Podkarpackie Voivodeship, Polonia, 37-700
- Reclutamiento
- Wojewodzki Szpital im. Sw. Ojca Pio w Przemyslu ( Site 1102)
-
Contacto:
- Study Coordinator
- Número de teléfono: +48166775000
-
-
-
-
-
Taichung, Taiwán, 404
- Reclutamiento
- China Medical University Hospital ( Site 0606)
-
Contacto:
- Study Coordinator
- Número de teléfono: +886422052121
-
Tainan, Taiwán, 70403
- Reclutamiento
- National Cheng Kung University Hospital ( Site 0601)
-
Contacto:
- Study Coordinator
- Número de teléfono: +88662353535
-
Taipei, Taiwán, 104
- Reclutamiento
- Mackay Memorial Hospital ( Site 0604)
-
Contacto:
- Study Coordinator
- Número de teléfono: +886225433535
-
Taipei, Taiwán, 11217
- Reclutamiento
- Taipei Veterans General Hospital ( Site 0602)
-
Contacto:
- Study Coordinator
- Número de teléfono: +88628712121
-
Taipei, Taiwán, 106
- Reclutamiento
- National Taiwan University Cancer Center (NTUCC) ( Site 0600)
-
Contacto:
- Study Coordinator
- Número de teléfono: +886223220322
-
Taoyuan, Taiwán, 33305
- Reclutamiento
- Chang Gung Medical Foundation-Linkou Branch ( Site 0605)
-
Contacto:
- Study Coordinator
- Número de teléfono: +88633281200
-
-
-
-
-
Ankara, Turquía (Türkiye), 06230
- Reclutamiento
- Hacettepe Universitesi Tıp Fakultesi ( Site 1400)
-
Contacto:
- Study Coordinator
- Número de teléfono: +905436067759
-
Ankara, Turquía (Türkiye), 06800
- Reclutamiento
- Ankara Bilkent Şehir Hastanesi ( Site 1402)
-
Contacto:
- Study Coordinator
- Número de teléfono: +905384724282
-
Ankara, Turquía (Türkiye), 06520
- Reclutamiento
- Memorial Ankara Hastanesi ( Site 1401)
-
Contacto:
- Study Coordinator
- Número de teléfono: +9005321332009
-
Istanbul, Turquía (Türkiye), 34010
- Reclutamiento
- Koç Üniversitesi Hastanesi ( Site 1403)
-
Contacto:
- Study Coordinator
- Número de teléfono: +905369410661
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
Inclusion Criteria include, but are not limited to:
- Has a histologically or cytologically confirmed diagnosis of squamous non-small cell lung cancer (NSCLC) (Stage IV: M1a, M1b, M1c1, M1c2, AJCC Staging Manual, Version 9). NOTE: Mixed tumors will be characterized by the predominant cell type; however, small cell elements are not permitted.
- Has measurable disease per Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by the local site investigator/radiology
- Has provided a tissue sample that is collected either at the time of or after the diagnosis of metastatic disease AND is from a site not previously irradiated
- Adverse events (AEs) due to previous anticancer therapies must have recovered to ≤Grade 1. Participants with endocrine-related AEs who are adequately treated with hormone replacement or participants who have ≤Grade 2 neuropathy are eligible
- Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on antiretroviral therapy (ART)
- Hepatitis B surface antigen (HBsAg) positive participants are eligible if they have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks, and have undetectable HBV viral load prior to randomization
- Participants with history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable. NOTE: Participants must have completed curative antiviral therapy at least 4 weeks prior to randomization
- Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 assessed within 7 days before randomization
- Has a life expectancy of at least 3 months
- Has adequate organ function
Exclusion Criteria:
Exclusion Criteria include, but are not limited to:
- Is HIV-infected with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
- Has received prior treatment with a cancer vaccine, including another personalized cancer vaccine (PCV)
- Has received prior systemic anticancer therapy for their metastatic NSCLC
- Has received prior therapy with an anti-programmed cell death 1 protein (anti-PD-1), anti-programmed cell death ligand 1 (anti-PD-L1), or anti-programmed cell death ligand 2 (anti-PD-L2) agent, or with an agent directed to another stimulatory or coinhibitory T-cell receptor. NOTE: Prior treatment with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent in the neoadjuvant or adjuvant setting for nonmetastatic NSCLC is allowed as long as therapy was completed at least 12 months before diagnosis of metastatic NSCLC
- Has received prior radiotherapy within 2 weeks of start of study intervention, or has radiation-related toxicities, requiring corticosteroids
- Has received radiation therapy to the lung that is >30 gray within 6 months of start of study intervention
- Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines is allowed
- Has received an investigational agent or has used an investigational device within 4 weeks prior to study intervention administration
- Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study intervention
- Has known additional malignancy that is progressing or has required active treatment within the past 3 years
- Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis
- Has severe hypersensitivity (≥Grade 3) to V940, pembrolizumab, or any of the protocol allowed chemotherapy agents and/or any of their excipients
- Has active autoimmune disease that has required systemic treatment in the past 2 years
- Has a history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease
- Has active infection requiring systemic therapy
- Has a history of stem cell/solid organ transplant
- Has not adequately recovered from major surgery or has ongoing surgical complications
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Triple
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Intismeran Autogene + Pembrolizumab + Chemo
Induction phase: Participants receive pembrolizumab 400 mg intravenous (IV) infusion on Day 1 of a six week cycle plus a platinum doublet chemotherapy regimen (carboplatin area under the curve (AUC) 6 or 5 mg/mL/min IV infusion every 3 weeks (Q3W) × 2 doses combined either with paclitaxel 200 or 175 mg/m^2 IV infusion Q3W × 2 doses, OR with nab paclitaxel 100 mg/m^2 IV infusion weekly × 6 doses). Intismeran Autogene 1 mg intramuscular (IM) injection is administered on Days 1 and 22 of Cycle 2 Induction (Q3W) for up to 2 doses. Maintenance phase: Participants receive pembrolizumab 400 mg IV infusion on Day 1 every 6 weeks (Q6W) for up to 15 doses. Intismeran Autogene 1 mg IM injection is administered on Days 1 and 22 (Q3W) for up to 7 doses during maintenance. |
1 mg Intramuscular (IM) Injection
Otros nombres:
200 mg IV Infusion
Otros nombres:
Area Under the Curve (AUC) either 6 or 5 (mg/mL/min) IV Infusion 200 or 175 mg/m^2 IV Infusion 100 mg/m^2 IV Infusion |
|
Experimental: Placebo + Pembrolizumab + Chemo
Induction phase: Participants receive pembrolizumab 400 mg intravenous (IV) infusion on Day 1 of a six week cycle plus a platinum doublet chemotherapy regimen (carboplatin area under the curve (AUC) 6 or 5 mg/mL/min IV infusion every 3 weeks (Q3W) × 2 doses combined either with paclitaxel 200 or 175 mg/m^2 IV infusion Q3W × 2 doses, OR with nab paclitaxel 100 mg/m^2 IV infusion weekly × 6 doses). Placebo intramuscular (IM) injection is administered on Days 1 and 22 of Cycle 2 Induction (Q3W) for up to 2 doses. Maintenance phase: Participants receive pembrolizumab 400 mg IV infusion on Day 1 every 6 weeks (Q6W) for up to 15 doses. Placebo IM injection is administered on Days 1 and 22 (Q3W) for up to 7 doses during maintenance. |
200 mg IV Infusion
Otros nombres:
Area Under the Curve (AUC) either 6 or 5 (mg/mL/min) IV Infusion 200 or 175 mg/m^2 IV Infusion 100 mg/m^2 IV Infusion Placebo matched to Intismeran Autogene IM injection |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Progression Free Survival (PFS)
Periodo de tiempo: Up to ~32 months
|
PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first as assessed by Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1). PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS as assessed by blinded independent central review (BICR) will be presented. |
Up to ~32 months
|
|
Overall Survival (OS)
Periodo de tiempo: Up to ~42 months
|
OS, defined as the time from randomization to death due to any cause. OS will be presented. |
Up to ~42 months
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Overall Response Rate (ORR)
Periodo de tiempo: Up to ~26 months
|
ORR is defined as the percentage of participants with Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1. The percentage of participants who experience CR or PR as assessed by BICR will be presented. |
Up to ~26 months
|
|
Duration of Response (DOR)
Periodo de tiempo: Up to ~42 months
|
For participants who demonstrate a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR is defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. DOR as assessed by BICR will be presented. |
Up to ~42 months
|
|
Number of Participants who Experience an Adverse Event (AE)
Periodo de tiempo: Up to ~42 months
|
An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who experience an AE will be presented. |
Up to ~42 months
|
|
Number of Participants who Discontinue Study Intervention Due to an AE
Periodo de tiempo: Up to ~24 months
|
An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who discontinue study intervention due to an AE will be presented. |
Up to ~24 months
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Director de estudio: Medical Director, Merck Sharp & Dohme LLC
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- V940-013
- V940-013 (Otro identificador: MSD)
- U1111-1318-2495 (Identificador de registro: UTN)
- 2025-520902-37-00 (Identificador de registro: EU CT)
- 2025 (Subvención/contrato del NIH de EE. UU.)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .